Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010015/S574

Percepta Bipolar CRT-P W1TR01 NKE Percepta Quadripolar CRT-P W4TR01 NKE Serena Bipolar CRT-P W1TR02 NKE Serena Quadripol

Medtronic, Inc. · Decision date Dec 19, 2025

FDA DECISIONP010015/S574

What did the FDA approve?

FDA records P010015/S574 as a supplement to PMA P010015, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Dec 19, 2025.

FDA approval order statement

approval for a material change in the pulse generator header components of select CRT-D and CRT-P devices.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Dec 19, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P010015/S574
Regulatory pathway
PMA supplement
Product code
LWP
Decision code
APPR
Decision date
Dec 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable pulse generator, pacemaker (non-CRT).

Product code
LWP
FDA device class
3

For the original device and its historical approval scope, see PMA P010015. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010015 · Original PMA

    MEDTRONIC INSYNC(TM) BIVENTRICAL PACING SYSTEM

  2. P010015/S567 · Related supplement

    Consulta CRT-P (C4TR01); Syncra CRT-P (C2TR01)

  3. P010015/S568 · Related supplement

    Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CR T-

  4. P010015/S569 · Related supplement

    Consulta CRT-P C4TR01; Percepta Bipolar CRT-P W1TR01; Percepta Quadripolar CRT-P W4TR01; Serena Bipolar CRT-P W1TR02; Se

  5. P010015/S570 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRTP (W1TR02); Serena Quadripolar C

  6. P010015/S574 received

    Application receipt date recorded by FDA.

  7. P010015/S571 · Related supplement

    Percepta Bipolar CRTP; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P;

  8. P010015/S572 · Related supplement

    Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Sola

  9. P010015/S573 · Related supplement

    Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Sola

  10. P010015/S575 · Related supplement

    Percepta Bipolar CRT-P W1TR01 NKE Percepta Quadripolar CRT-P W4TR01 NKE Serena Bipolar CRT-P W1TR02 NKE Serena Quadripol

  11. P010015/S574 · FDA decision

    Normal 180 Day Track

  12. P010015/S576 · Related supplement

    Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRTP; Serena Quadripolar CRT-P; Solar

  13. P010015/S577 · Related supplement

    Percepta Bipolar CRT-P; Perceota Quadrioolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

  14. P010015/S578 · Related supplement

    Consulta CRT-P (C4TR01); Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1T

  15. P010015/S579 · Related supplement

    Attain OTW LV Lead; Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Qua

  16. P010015/S580 · Related supplement

    Consulta CRT-P C4TR01 Syncra CRT-P C2TR01

  17. P010015/S582 · Related supplement

    Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

  18. P010015/S584 · Related supplement

    Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

  19. P010015/S586 · Related supplement

    Attain Bipolar OTW Lead; Attain OTW L V Lead

  20. P010015/S585 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRTP (W1TR02); Serena Quadripolar C

  21. P010015/S581 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar

  22. P010015/S583 · Related supplement

    Percepta Bipolar CRT-P (WlTR0l); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (WlTR02); Serena Quadripolar

  23. P010015/S587 · Related supplement

    Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P

  24. P010015/S588 · Related supplement

    Consulta CRT-P (C4TR01); Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1T

  25. P010015/S589 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar

  26. P010015/S590 · Related supplement

    Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P

  27. P010015/S591 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar

  28. P010015/S592 · Related supplement

    Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

Timeline entries are records held by MedtechLedger for P010015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010015

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalAug 28, 2001FDA
Medtronic, Inc.PMA supplementAug 6, 2025FDA
Medtronic, Inc.PMA supplementAug 12, 2025FDA
Medtronic, Inc.PMA supplementAug 12, 2025FDA
Medtronic, Inc.PMA supplementSep 5, 2025FDA
Medtronic, Inc.PMA supplementOct 2, 2025FDA
Medtronic, Inc.PMA supplementOct 3, 2025FDA
Medtronic, Inc.PMA supplementOct 8, 2025FDA
Medtronic, Inc.PMA supplementDec 3, 2025FDA
Medtronic, Inc.PMA supplementJan 23, 2026FDA
Medtronic, Inc.PMA supplementJan 23, 2026FDA
Medtronic, Inc.PMA supplementFeb 10, 2026FDA
Medtronic, Inc.PMA supplementFeb 10, 2026FDA
Medtronic, Inc.PMA supplementFeb 12, 2026FDA
Medtronic, Inc.PMA supplementMar 6, 2026FDA
Medtronic, Inc.PMA supplementMar 27, 2026FDA
Medtronic, Inc.PMA supplementApr 15, 2026FDA
Medtronic, Inc.PMA supplementApr 23, 2026FDA
Medtronic, Inc.PMA supplementApr 30, 2026FDA
Medtronic, Inc.PMA supplementMay 14, 2026FDA
Medtronic, Inc.PMA supplementJul 16, 2026FDA
Medtronic, Inc.PMA supplementJul 31, 2026FDA
Medtronic, Inc.PMA supplementJul 31, 2026FDA
Medtronic, Inc.PMA supplementOct 5, 2026FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA
Medtronic, Inc.PMA supplementOct 29, 2026FDA

Explore the linked device profile

Other records with product code LWP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records